Ubrogepant + ERENUMAB for migraine disorders

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 26 Sep 2019: Trial started, NCT04179474
  2. 27 Nov 2019: Trial registered, NCT04179474

The trials

NCT04179474: Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine

State
Completed
Phase
Phase 1
People
40 taking part
Started
26 Sep 2019
Primary completion
23 Dec 2019
Arms
Part 1 (Intervention A then B then D)
Results
Posted on the registry
  1. 26 Sep 2019: Trial started
  2. 27 Nov 2019: Trial registered
  3. 23 Dec 2019: Trial completed
  4. 10 Mar 2021: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.